Table 1. Characteristics of study sites in Senegal, Niger and Mali used in this study.

Country	Study type	Site/s	N children	Baseline uninfected (%)	Baseline single S. haematobium (%)	Baseline single S. mansoni (%)	Baseline co-infected (%)
Senegal	PZQ efficacy	Temeye	89	0	21.3	19.1	59.6
		Nder	107	0	0	2.8	97.2
Niger	PZQ efficacy	Diambala	180	0	22.2	24.4	53.3
		Namarigoungou	223	0	13.5	40.4	46.2
Mali	Monitoring & evaluation of national treatment programme	29 co-endemic schools in three regions (Bamako, Koulikoro and Ségou), 20 of which followed annually for 3 years.	2477	28.5	45	5.5	21